Sensitivity of BA.2.86 to prevailing neutralising antibody responses
D. J. Sheward, Y. Yang, M. Westerberg, S. Öling, S. Muschiol, K. Sato, T. P. Peacock, G. B. Karlsson Hedestam, J. Albert, B. Murrell
Abstract
A new SARS-CoV-2 variant, designated BA.2.86, has recently emerged with over 30 spike mutations relative to its parental BA.2, raising questions about its degree of resistance to neutralising antibodies. Using a spike-pseudotyped virus model we characterise neutralisation of BA.2.86 by clinically relevant monoclonal antibodies and by two cohorts of serum sampled from Stockholm, including both a recent cohort, and one sampled prior to the arrival of XBB in Sweden.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Neutralisation sensitivity of the SARS-CoV-2 BA.2.87.1 variant
D. J. Sheward, U. Marking, … B. Murrell·bioRxiv·Mar 21, 2024
- Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike
- Transmissibility, infectivity, and immune resistance of the SARS-CoV-2 BA.2.86 variant
- The impact of Spike mutations on SARS-CoV-2 neutralization
C. Rees-Spear, L. Muir, … L. E. McCoy·bioRxiv·Jan 15, 2021
- Neutralisation of SARS-CoV-2 Omicron subvariants BA.2.86 and EG.5.1 by antibodies induced by earlier infection or vaccination
R. Lassauniere, C. Polacek, … M. Rasmussen·bioRxiv·Oct 1, 2023
- Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.2.86
N. Lasrado, A.-r. Collier, … D. H. Barouch·bioRxiv·Sep 4, 2023